Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Tafolecimab for immunotherapy-failure advanced NSCLC
ChiCTR2400085872Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and tafolecimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Objective response rate (ORR) and Safety. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimabtafolecimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085872.